WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) announced that DYNE-251, an investigational therapeutic for Duchenne muscular dystrophy mutations amenable to exon 51 skipping, was granted FDA orphan drug and rare pediatric disease designations. DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial.
Under the FDA's rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor who receives a product approval for a rare pediatric disease.
Wildon Farwell, chief medical officer of Dyne, said: 'We continue to advance our DELIVER clinical trial and look forward to sharing initial clinical data later this year.'
For More Such Health News, visit rttnews.com.
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX